Androgen deprivation therapy (ADT) for prostate cancer can exacerbate cardiac risk factors and may increase the risk of heart attack and cardiac death, according to an advisory supported by four medical organizations.
ADP Raises CHD Risk
Proteinuria Matters
The three-year risk of death, heart attack, and kidney failure was markedly increased in patients with baseline proteinuria, regardless of their estimated glomerular filtration rate (eGFR), researchers said.
In a population-based study of nearly 1 million people, mortality was approximately doubled with heavy proteinuria among individuals stratified according to their eGFR, reported Brenda R. Hemmelgarn, MD, PhD, of the University of Calgary in Canada, and colleagues.
Rates of myocardial infarction were increased by about 50% with heavy proteinuria, and end-stage renal disease and doubled levels of serum creatinine were as much as 30 times more common, the researchers reported in the Feb. 3 issue of the Journal of the American Medical Association.
Tysabri (Natalizumab) and PML – Update
A warning of a risk of progressive multifocal leukoencephalopathy has been added to the label for the multiple sclerosis drug natalizumab (Tysabri), the FDA announced. The labeling change was prompted by continuing reports of PML in MS patients. The current number of confirmed cases stands at 31 — 10 in the U.S. — up from 13 as recently as last September.
Severe OSA = Brain Damage
Brain Damage Seen in People With Severe Sleep Apnea – BusinessWeek
Hey, it’s only the cerebral cortex where your information processing occurs.
It’s only your CPU that loses gray matter.
Small sample, just 36 men. Yeah, go ahead and skip the CPAP tonight.
You’re in Good Hands (or not)
Scary Chart of the Day – 2/5/10
Chart courtesy of:
Recovery?
NAFLD = Higher Mortality Rate
Thrombosis Journal – New Link
I’ve added a new link to a journal I uncovered while working on one of my projects.
http://www.thrombosisjournal.com/
A journal devoted to thrombosis. Is this cool or what?
You must be logged in to post a comment.